Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2003 2
2004 5
2005 2
2006 3
2007 4
2008 1
2009 6
2010 8
2011 13
2012 19
2013 20
2014 28
2015 19
2016 25
2017 12
2018 9
2019 5
2020 6
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 23369055

172 results
Results by year
Filters applied: . Clear all
Page 1
A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Flachenecker P. Flachenecker P. Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):15-9. doi: 10.1586/ern.13.1. Expert Rev Neurother. 2013. PMID: 23369055 Review.
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.
García-Merino A. García-Merino A. Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):9-13. doi: 10.1586/ern.13.4. Expert Rev Neurother. 2013. PMID: 23369054 Review.
Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
Slof J, Gras A. Slof J, et al. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):439-41. doi: 10.1586/erp.12.40. Epub 2012 Jun 8. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 22681512
Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
Arroyo R, Vila C, Dechant KL. Arroyo R, et al. J Comp Eff Res. 2014 Jul;3(4):435-44. doi: 10.2217/cer.14.30. J Comp Eff Res. 2014. PMID: 25275238 Review.
Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
Pozzilli C. Pozzilli C. Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Expert Rev Neurother. 2013. PMID: 24289844 Review.
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P. Vermersch P. Expert Rev Neurother. 2011 Apr;11(4 Suppl):15-9. doi: 10.1586/ern.11.27. Expert Rev Neurother. 2011. PMID: 21449855 Review.
Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
Slof J, Ruiz L, Vila C. Slof J, et al. Expert Rev Pharmacoecon Outcomes Res. 2015 Jun;15(3):379-91. doi: 10.1586/14737167.2015.1025759. Epub 2015 Mar 16. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25771713
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P, Henze T, Zettl UK. Flachenecker P, et al. Eur Neurol. 2014;71(5-6):271-9. doi: 10.1159/000357427. Epub 2014 Feb 12. Eur Neurol. 2014. PMID: 24525548
Multiple sclerosis spasticity daily management: retrospective data from Europe.
Berger T. Berger T. Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):3-7. doi: 10.1586/ern.13.3. Expert Rev Neurother. 2013. PMID: 23369053 Review.
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY, McKeage K, Scott LJ. Syed YY, et al. Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Drugs. 2014. PMID: 24671907 Review.
172 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback